{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T02:12:15Z","timestamp":1792980735232,"version":"4.5.0"},"reference-count":36,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100018786","name":"Scientific Research Deanship at the Al-Zaytoonah University of Jordan","doi-asserted-by":"publisher","award":["20\/23\/2019-2020"],"award-info":[{"award-number":["20\/23\/2019-2020"]}],"id":[{"id":"10.13039\/501100018786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>There is an alarming spread of cases of lipid disorders in the world that\noccur due to harmful lifestyle habits, hereditary risk influences, or as a result of other illnesses or\nmedicines. Cholesteryl Ester Transfer Protein (CETP) is a 476-residue lipophilic glycoprotein that\nhelps in the transport of cholesteryl ester and phospholipids from the atheroprotective HDL to the\nproatherogenic LDL and VLDL. Inhibition of CETP leads to elevation of HDL cholesterol and reduction\nof LDL cholesterol and triglycerides; therefore, it is considered a good target for the treatment\nof hyperlipidemia and its comorbidities.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>In this research, synthesis, characterization, molecular modeling, and biological evaluation\nof eight 3,5-bis(trifluoromethyl)benzylamino benzamides 9a-d and 10a-d were carried out.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>The synthesized molecules were characterized using 1H-NMR, 13C-NMR, IR, and HR-MS.\nThey were biologically tested in vitro to estimate their CETP inhibitory activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>These compounds offered inhibitory effectiveness ranging from 42.2% to 100% at a concentration\nof 10 \u03bcM. Compounds bearing unsubstituted three aromatic rings (9a) or ortho-CF3 substituted\n(9b) were the most effective compounds among their analogs and showed IC50 values of 1.36 and\n0.69 \u03bcM, respectively. The high docking scores of 9a-d and 10a-d against 4EWS imply that they\nmight be possible CETP inhibitors. Pharmacophore mapping results demonstrate that the series approves\nthe fingerprint of CETP active inhibitors and therefore explains their high binding affinity\nagainst CETP binding site.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>This work concludes that 3,5-bis(trifluoromethyl)benzylamino benzamides can serve as\na promising CETP inhibitor lead compound.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406417666210830125431","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T09:28:11Z","timestamp":1630402091000},"page":"417-426","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Synthesis and Molecular Modeling of Novel 3,5-Bis(trifluoromethyl)\nbenzylamino Benzamides as Potential CETP Inhibitors"],"prefix":"10.2174","volume":"18","author":[{"given":"Reema Abu","family":"Khalaf","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Al-Qirim","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dima","family":"Sabbah","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Faculty of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacl.2019.11.001","volume":"14","author":"Dyrbu\u015b K.","year":"2020","unstructured":"Dyrbu\u015b K.; G\u0105sior M.; Penson P.; Ray K.K.; Banach M.; Inclisiran-New hope in the management of lipid disorders? J Clin Lipidol 2020,14(1),16-27","journal-title":"J Clin Lipidol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"R49","DOI":"10.1093\/hmg\/ddz132","volume":"28","author":"Tirronen A.","year":"2019","unstructured":"Tirronen A.; Hokkanen K.; Vuorio T.; Yl\u00e4-Herttuala S.; Recent advances in novel therapies for lipid disorders. Hum Mol Genet 2019,28(R1),R49-R54","journal-title":"Hum Mol Genet"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cmet.2016.01.005","volume":"23","author":"Rader D.J.","year":"2016","unstructured":"Rader D.J.; New therapeutic approaches to the treatment of dyslipidemia. Cell Metab 2016,23(3),405-412","journal-title":"Cell Metab"},{"key":"ref=4","author":"Martinez-Hervas S.","year":"2019","unstructured":"Martinez-Hervas S.; Ascaso J.F.; Hypercholesterolemia. 2019"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","volume":"41","author":"Laufs U.","year":"2020","unstructured":"Laufs U.; Parhofer K.G.; Ginsberg H.N.; Hegele R.A.; Clinical review on triglycerides. Eur Heart J 2020,41(1),99-109c","journal-title":"Eur Heart J"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1177\/0003319718779533","volume":"70","author":"Kypreos K.E.","year":"2019","unstructured":"Kypreos K.E.; Bitzur R.; Karavia E.A.; Xepapadaki E.; Panayiotakopoulos G.; Constantinou C.; Pharmacological management of dyslipidemia in atherosclerosis: Limitations, challenges, and new therapeutic opportunities. Angiology 2019,70(3),197-209","journal-title":"Angiology"},{"key":"ref=7","first-page":"S139","volume":"23","author":"Karr S.","year":"2017","unstructured":"Karr S.; Epidemiology and management of hyperlipidemia. Am J Manag Care 2017,23(9)(Suppl.),S139-S148","journal-title":"Am J Manag Care"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/B978-0-323-29738-7.00037-X","author":"Semenkovich C.F.","year":"2016","unstructured":"Semenkovich C.F.; Goldberg A.C.; Goldberg I.J.; Disorders of\nlipid metabolism. Williams textbook of endocrinology 2016,1660-1700","journal-title":"Williams textbook of endocrinology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cca.2013.12.001","volume":"429","author":"P\u00e9rez-M\u00e9ndez \u00d3.","year":"2014","unstructured":"P\u00e9rez-M\u00e9ndez \u00d3.; Pacheco H.G.; Mart\u00ednez-S\u00e1nchez C.; Franco M.; HDL-cholesterol in coronary artery disease risk: Function or structure? Clin Chim Acta 2014,429,111-122","journal-title":"Clin Chim Acta"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/07853890.2019.1694695","volume":"51","author":"Sirtori C.R.","year":"2019","unstructured":"Sirtori C.R.; Ruscica M.; Calabresi L.; Chiesa G.; Giovannoni R.; Badimon J.J.; HDL therapy today: From atherosclerosis, to stent compatibility to heart failure. Ann Med 2019,51(7-8),345-359","journal-title":"Ann Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0003319719854609","volume":"71","author":"Xepapadaki E.","year":"2020","unstructured":"Xepapadaki E.; Zvintzou E.; Kalogeropoulou C.; Filou S.; Kypreos K.E.; The antioxidant function of HDL in atherosclerosis. Angiology 2020,71(2),112-121","journal-title":"Angiology"},{"key":"ref=12","unstructured":"Feingold, K.R.; Grunfeld, C. Introduction to lipids and lipoproteins. Endotext; MDText. com, Inc., 2018."},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1194\/jlr.R039297","volume":"55","author":"Rye K-A.","year":"2014","unstructured":"Rye K-A.; Barter P.J.; Cardioprotective functions of HDLs. J Lipid Res 2014,55(2),168-179","journal-title":"J Lipid Res"},{"key":"ref=14","author":"Zhyvotovska A.","year":"2019","unstructured":"Zhyvotovska A.; Yusupov D.; McFarlane S.I.;  Introductory chapter: Overview of lipoprotein metabolismDyslipidemia 2019","journal-title":"Introductory chapter: Overview of lipoprotein metabolismDyslipidemia"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S32667","DOI":"10.4137\/CMC.S32667","volume":"10","author":"Kosmas C.E.","year":"2016","unstructured":"Kosmas C.E.; Dejesus E.; Rosario D.; Vittorio T.J.; CETP inhibition: Past failures and future hopes. Clin Med Insights Cardiol 2016,10,S32667","journal-title":"Clin Med Insights Cardiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/13543776.2018.1439476","volume":"28","author":"Wang X.","year":"2018","unstructured":"Wang X.; Li W.; Hao L.; Xie H.; Hao C.; Liu C.; Li W.; Xiong X.; Zhao D.; The therapeutic potential of CETP inhibitors: A patent review. Expert Opin Ther Pat 2018,28(4),331-340","journal-title":"Expert Opin Ther Pat"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"028702","DOI":"10.1088\/1674-1056\/27\/2\/028702","volume":"27","author":"Chen S-Y.","year":"2018","unstructured":"Chen S-Y.; Li N.; Jin T-L.; Gou L.; Hao D-X.; Tian Z-Q.; Lipoprotein in cholesterol transport: Highlights and recent insights into its structural basis and functional mechanism. Chin Phys B 2018,27(2),028702","journal-title":"Chin Phys B"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jsb.2016.02.016","volume":"194","author":"Lauer M.E.","year":"2016","unstructured":"Lauer M.E.; Graff-Meyer A.; Rufer A.C.; Maugeais C.; von der Mark E.; Matile H.; D\u2019Arcy B.; Magg C.; Ringler P.; M\u00fcller S.A.; Scherer S.; Dernick G.; Thoma R.; Hennig M.; Niesor E.J.; Stahlberg H.; Cholesteryl ester transfer between lipoproteins does not require a ternary tunnel complex with CETP. J Struct Biol 2016,194(2),191-198","journal-title":"J Struct Biol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.atherosclerosis.2018.09.035","volume":"278","author":"Yamashita S.","year":"2018","unstructured":"Yamashita S.; Ruscica M.; Macchi C.; Corsini A.; Matsuzawa Y.; Sirtori C.R.; Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Atherosclerosis 2018,278,286-298","journal-title":"Atherosclerosis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cpt.1118","volume":"104","author":"Nicholls S.J.","year":"2018","unstructured":"Nicholls S.J.; CETP-inhibition and hdl-cholesterol: A story of cv risk or cv benefit, or both. Clin Pharmacol Ther 2018,104(2),297-300","journal-title":"Clin Pharmacol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jvs.2017.11.029","volume":"67","author":"Bowman L.","year":"2018","unstructured":"Bowman L.; Hopewell J.; Chen F.; Wallendszus K.; Stevens W.; Effects of anacetrapib in patients with atherosclerotic vascular disease. J Vasc Surg 2018,67(1),356","journal-title":"J Vasc Surg"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"Bowman L.","year":"2017","unstructured":"Bowman L.; Hopewell J.C.; Chen F.; Wallendszus K.; Stevens W.; Collins R.; Wiviott S.D.; Cannon C.P.; Braunwald E.; Sammons E.; Landray M.J.; Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017,377(13),1217-1227","journal-title":"N Engl J Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.atherosclerosis.2017.01.011","volume":"257","author":"Simic B.","year":"2017","unstructured":"Simic B.; Mocharla P.; Crucet M.; Osto E.; Kratzer A.; Stivala S.; K\u00fchnast S.; Speer T.; Doycheva P.; Princen H.M.; van der Hoorn J.W.; Jukema J.W.; Giral H.; Tailleux A.; Landmesser U.; Staels B.; L\u00fcscher T.F.; Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Atherosclerosis 2017,257,186-194","journal-title":"Atherosclerosis"},{"key":"ref=24","author":"Dube M-P.","year":"2018","unstructured":"Dube M-P.; Niesor E.J.; Tardif J-C.; Upmanyu R.;  Dalcetrapib for therapeutic use 2018","journal-title":"Dalcetrapib for therapeutic use"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.ejmech.2009.12.070","volume":"45","author":"Abu Khalaf R.","year":"2010","unstructured":"Abu Khalaf R.; Abu Sheikha G.; Bustanji Y.; Taha M.O.; Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Eur J Med Chem 2010,45(4),1598-1617","journal-title":"Eur J Med Chem"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.3390\/molecules15085721","volume":"15","author":"Abu Sheikha G.","year":"2010","unstructured":"Abu Sheikha G.; Abu Khalaf R.; Melhem A.; Albadawi G.; Design, synthesis, and biological evaluation of benzylamino-methanone based cholesteryl ester transfer protein inhibitors. Molecules 2010,15(8),5721-5733","journal-title":"Molecules"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00044-011-9917-5","volume":"21","author":"Abu Khalaf R.","year":"2012","unstructured":"Abu Khalaf R.; Abu Sheikha G.; Al-Sha\u2019er M.; Albadawi G.; Taha M.; Design, synthesis, and biological evaluation of sulfonic acid ester and benzenesulfonamide derivatives as potential CETP inhibitors. Med Chem Res 2012,21(11),3669-3680","journal-title":"Med Chem Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.2174\/1570180814666170412122304","volume":"14","author":"Abu Khalaf R.","year":"2017","unstructured":"Abu Khalaf R.; Abd El-Aziz H.; Sabbah D.; Albadawi G.; Abu Sheikha G.; CETP inhibitory activity of chlorobenzyl benzamides: QPLD docking, pharmacophore mapping and synthesis. Lett Drug Des Discov 2017,14(12),1391-1400","journal-title":"Lett Drug Des Discov"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1700204","DOI":"10.1002\/ardp.201700204","volume":"350","author":"Abu Khalaf R.","year":"2017","unstructured":"Abu Khalaf R.; Sabbah D.; Al-Shalabi E.; Bishtawi S.; Albadawi G.; Abu Sheikha G.; Synthesis, biological evaluation, and molecular modeling study of substituted benzyl benzamides as CETP inhibitors. Arch Pharm (Weinheim) 2017,350(12),1700204","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=30","author":"Abu Khalaf R.","year":"2020","unstructured":"Abu Khalaf R.; NasrAllah, A.; Jarrar, W.; Sabbah, D. CETP inhibitory oxoacetamido-benzamide derivatives: Glide docking, pharmacophore mapping, and synthesis. Braz J Pharm Sci 2020","journal-title":"Braz J Pharm Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2174\/1573406412666161104121042","volume":"13","author":"Khalaf R.A.","year":"2017","unstructured":"Khalaf R.A.; Al-Rawashdeh S.; Sabbah D.; Abu Sheikha G.; Molecular docking and pharmacophore modeling studies of fluorinated benzamides as potential CETP inhibitors. Med Chem 2017,13(3),239-253","journal-title":"Med Chem"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"37321","DOI":"10.1074\/jbc.M112.380063","volume":"287","author":"Liu S.","year":"2012","unstructured":"Liu S.; Mistry A.; Reynolds J.M.; Lloyd D.B.; Griffor M.C.; Perry D.A.; Ruggeri R.B.; Clark R.W.; Qiu X.; Crystal structures of cholesteryl ester transfer protein in complex with inhibitors. J Biol Chem 2012,287(44),37321-37329","journal-title":"J Biol Chem"},{"key":"ref=33","first-page":"97204","year":"2016","unstructured":"Schr\u00f6dinger Protein Preparation Wizard, Maestro, Macromodel, QPLD-dock, and Pymol 2016,97204","journal-title":"Schr\u00f6dinger Protein Preparation Wizard, Maestro, Macromodel, QPLD-dock, and Pymol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"Friesner R.A.","year":"2004","unstructured":"Friesner R.A.; Banks J.L.; Murphy R.B.; Halgren T.A.; Klicic J.J.; Mainz D.T.; Repasky M.P.; Knoll E.H.; Shelley M.; Perry J.K.; Shaw D.E.; Francis P.; Shenkin P.S.; Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004,47(7),1739-1749","journal-title":"J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1021\/jm051256o","volume":"49","author":"Friesner R.A.","year":"2006","unstructured":"Friesner R.A.; Murphy R.B.; Repasky M.P.; Frye L.L.; Greenwood J.R.; Halgren T.A.; Sanschagrin P.C.; Mainz D.T.; Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 2006,49(21),6177-6196","journal-title":"J Med Chem"},{"key":"ref=36","unstructured":"The Molecular operating, Environment Chemical Computing Group; Inc Montreal: Quebec, Canada, 2016."}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210830125431","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/195939\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406417666210830125431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T06:47:12Z","timestamp":1666939632000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/195939\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406417666210830125431","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-02-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}